Novo Nordisk shares slide again as Wegovy pill misses expectations

Shares in Danish drugmaker Novo Nordisk are falling again, partly due to disappointing trial results for the oral version of its weight-loss drug Wegovy. The company did, however, raise its full-year outlook. Investor disappointment centres on the pill's potential as an alternative to semaglutide injections.